Progressive (PGR) Form 144 Reports 6,420-Share Sale From Vesting
Rhea-AI Filing Summary
Progressive Corp (PGR) Form 144 notice: An individual, Patrick Callahan, submitted a Form 144 reporting the proposed sale of 6,420 shares of Progressive common stock through Fidelity Brokerage Services on the NYSE with an aggregate market value of $1,555,041.08. Those shares were acquired on 07/25/2025 upon restricted stock vesting and are characterized as compensation. The filer previously sold 6,232 shares on 07/28/2025 for $1,509,139.19 and 6,232 shares on 08/22/2025 for $1,557,748.72. The notice includes the seller’s representation about absence of undisclosed material information.
Positive
- Transaction arises from restricted stock vesting, indicating the sale is compensation-related rather than an opportunistic disposal.
- Brokerage through Fidelity and reporting on Form 144 demonstrate compliance with Rule 144 disclosure requirements.
Negative
- Multiple recent sales reported (07/28/2025 and 08/22/2025) in addition to the proposed 09/19/2025 sale, which may attract investor attention despite being small relative to outstanding shares.
Insights
TL;DR: Routine insider sale from vested restricted compensation; size is immaterial to market capitalization.
The filing shows a planned sale of 6,420 shares arising from restricted stock vesting on 07/25/2025, to be executed via Fidelity on 09/19/2025, with an aggregate market value of $1,555,041.08. Prior near-term disposals of 6,232 shares on 07/28/2025 and 6,232 shares on 08/22/2025 are disclosed, indicating ongoing disposition of vested compensation. Relative to the reported 586,208,487 shares outstanding, these transactions are immaterial to share supply and likely reflect routine executive or employee compensation monetization rather than a change in company fundamentals.
TL;DR: Disclosure aligns with Rule 144 requirements; seller makes required representation regarding material nonpublic information.
The notice documents mandatory Rule 144 disclosures: acquisition date, nature (restricted stock vesting), and planned sale details. The seller’s attestation that no undisclosed material adverse information exists is included. Multiple recent sales are reported, which is appropriate for transparency and compliance. No indications of trading plan dates or 10b5-1 reliance are provided in the form, so reliance on a prearranged plan is not confirmed in this filing.